NeuroPace (NPCE) to Release Quarterly Earnings on Tuesday

NeuroPace (NASDAQ:NPCE) is projected to release its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $22.6130 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. The firm had revenue of $22.00 million during the quarter, compared to analysts’ expectations of $21.65 million. NeuroPace had a negative net margin of 21.67% and a negative return on equity of 108.20%.

NeuroPace Stock Up 2.1%

NASDAQ:NPCE traded up $0.28 during trading hours on Tuesday, reaching $13.78. The company’s stock had a trading volume of 60,627 shares, compared to its average volume of 202,962. The company has a debt-to-equity ratio of 4.08, a current ratio of 5.38 and a quick ratio of 4.35. The company has a market cap of $469.86 million, a price-to-earnings ratio of -21.19 and a beta of 1.92. NeuroPace has a one year low of $7.56 and a one year high of $19.60. The business’s 50-day moving average is $15.84 and its 200-day moving average is $15.51.

Hedge Funds Weigh In On NeuroPace

Large investors have recently bought and sold shares of the business. Engineers Gate Manager LP bought a new stake in NeuroPace during the 4th quarter valued at $188,000. Price T Rowe Associates Inc. MD lifted its stake in shares of NeuroPace by 23.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,836 shares of the company’s stock valued at $230,000 after buying an additional 2,778 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of NeuroPace during the fourth quarter valued at about $185,000. PharVision Advisers LLC purchased a new position in shares of NeuroPace during the third quarter valued at approximately $232,000. Finally, Aquatic Capital Management LLC bought a new position in NeuroPace during the 3rd quarter valued at $229,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on NPCE shares. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of NeuroPace in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a report on Wednesday, June 24th. Mizuho started coverage on shares of NeuroPace in a research note on Thursday, July 23rd. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, Guggenheim reissued a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.29.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.